BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 23190281)

  • 21. Investigations of Huntington's Disease and Huntington's Disease-Like Syndromes in Indian Choreatic Patients.
    Kaur J; Parveen S; Shamim U; Sharma P; Suroliya V; Sonkar AK; Ahmad I; Garg J; Anand KS; Laskar S; Chowdhury D; Kushwaha S; Goyal V; Srivastava AK; Singh G; Faruq M
    J Huntingtons Dis; 2020; 9(3):283-289. PubMed ID: 32675418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice.
    Kovalenko M; Dragileva E; St Claire J; Gillis T; Guide JR; New J; Dong H; Kucherlapati R; Kucherlapati MH; Ehrlich ME; Lee JM; Wheeler VC
    PLoS One; 2012; 7(9):e44273. PubMed ID: 22970194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induced Pluripotent HD Monkey Stem Cells Derived Neural Cells for Drug Discovery.
    Kunkanjanawan T; Carter R; Ahn KS; Yang J; Parnpai R; Chan AWS
    SLAS Discov; 2017 Jul; 22(6):696-705. PubMed ID: 28027448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
    Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
    J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models.
    Sontag EM; Lotz GP; Agrawal N; Tran A; Aron R; Yang G; Necula M; Lau A; Finkbeiner S; Glabe C; Marsh JL; Muchowski PJ; Thompson LM
    J Neurosci; 2012 Aug; 32(32):11109-19. PubMed ID: 22875942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.
    Garriga-Canut M; Agustín-Pavón C; Herrmann F; Sánchez A; Dierssen M; Fillat C; Isalan M
    Proc Natl Acad Sci U S A; 2012 Nov; 109(45):E3136-45. PubMed ID: 23054839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length.
    de Almeida LP; Ross CA; Zala D; Aebischer P; Déglon N
    J Neurosci; 2002 May; 22(9):3473-83. PubMed ID: 11978824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
    Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
    J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).
    Ratovitski T; Arbez N; Stewart JC; Chighladze E; Ross CA
    Cell Cycle; 2015; 14(11):1716-29. PubMed ID: 25927346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.
    Rising AC; Xu J; Carlson A; Napoli VV; Denovan-Wright EM; Mandel RJ
    Exp Neurol; 2011 Apr; 228(2):173-82. PubMed ID: 21192926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential Transfer of Polyglutamine and CAG-Repeat RNA in Extracellular Vesicles in Huntington's Disease: Background and Evaluation in Cell Culture.
    Zhang X; Abels ER; Redzic JS; Margulis J; Finkbeiner S; Breakefield XO
    Cell Mol Neurobiol; 2016 Apr; 36(3):459-70. PubMed ID: 26951563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple phenotypes in Huntington disease mouse neural stem cells.
    Ritch JJ; Valencia A; Alexander J; Sapp E; Gatune L; Sangrey GR; Sinha S; Scherber CM; Zeitlin S; Sadri-Vakili G; Irimia D; Difiglia M; Kegel KB
    Mol Cell Neurosci; 2012 May; 50(1):70-81. PubMed ID: 22508027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.
    Chang R; Liu X; Li S; Li XJ
    Drug Des Devel Ther; 2015; 9():2179-88. PubMed ID: 25931812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive Polyglutamine Repeat Expansion in Peripheral Blood Cells and Sperm of Transgenic Huntington's Disease Monkeys.
    Clever F; Cho IK; Yang J; Chan AWS
    J Huntingtons Dis; 2019; 8(4):443-448. PubMed ID: 31561381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transgenic rat model of Huntington's disease.
    von Hörsten S; Schmitt I; Nguyen HP; Holzmann C; Schmidt T; Walther T; Bader M; Pabst R; Kobbe P; Krotova J; Stiller D; Kask A; Vaarmann A; Rathke-Hartlieb S; Schulz JB; Grasshoff U; Bauer I; Vieira-Saecker AM; Paul M; Jones L; Lindenberg KS; Landwehrmeyer B; Bauer A; Li XJ; Riess O
    Hum Mol Genet; 2003 Mar; 12(6):617-24. PubMed ID: 12620967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversal of cellular phenotypes in neural cells derived from Huntington's disease monkey-induced pluripotent stem cells.
    Carter RL; Chen Y; Kunkanjanawan T; Xu Y; Moran SP; Putkhao K; Yang J; Huang AH; Parnpai R; Chan AW
    Stem Cell Reports; 2014 Oct; 3(4):585-93. PubMed ID: 25358787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An ovine transgenic Huntington's disease model.
    Jacobsen JC; Bawden CS; Rudiger SR; McLaughlan CJ; Reid SJ; Waldvogel HJ; MacDonald ME; Gusella JF; Walker SK; Kelly JM; Webb GC; Faull RL; Rees MI; Snell RG
    Hum Mol Genet; 2010 May; 19(10):1873-82. PubMed ID: 20154343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.